This is the chaotic December Spend-A-Thon

Morning Bullets header logo

Your daily source for trading strategies, tech news, and politically incorrect humor.

Hey there, Bullets Fans –

Your Morning Bullets Brief Updates are here! And that means trivia is, too.

On this day in 1930, what happened to the Bank of the United States?

Think you know the answer? You can check it in the closing area down below!

Morning Bullets - The Top 5 Things You Need To Know

Image Source: Morning Bullets

The FDA has said it “notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed, so they can execute their plans for timely vaccine distribution,” indicating that the official approval of Pfizer’s vaccine is on the way.

However, investors seem more focused this morning on the stimulus talks and the lack of any real movement on that front. The House adjourned until next week and the Senate Majority Leader indicated that Republicans were probably not going to vote for the bipartisan bill worth $908 billion.

The Dow Jones Industrial Average reflected that uncertainty this morning, as it was poised for a 150-point loss at open.

What else should you know this morning about the markets?

Other Top Financial News

It’s time for trades that win both ways


Recommended Link:
Don't Miss This!
INTRODUCING… the Win-Both-Ways Trade

When I left the Chicago Board Options Exchange years ago…

I brought the top strategies with me and went to work for everyday investors.

My first 3,765 trade recommendations averaged a 12.7% gain every three days…

12.7% – every three days – that’s what Goldman Sachs hopes to achieve every THREE YEARS.

But now, for the first time, I’m revealing my No. 1 secret for averaging nearly 3X more money…


Then my lifetime mark.

I’m talking about averaging single-day gains of 34.58%… with individual wins of up to 136%… 178%… and 188%… all in 24 hours…

See why I’m calling this technique “the Win-Both-Ways Trade.”

And why Charles Schwab is calling it “a breakout strategy.”


The latest on the road to vaccine approval

Image Source: Reuters

Members of a Food and Drug Administration advisory panel voted 17-4 to recommend approval of Pfizer’s vaccine. Yesterday’s much-anticipated meeting of the Vaccines and Related Biological Products Advisory Committee marks the final step before the FDA decides whether to grant emergency use authorization of the drug.

That final stamp of approval could even come today, an expert says.

It remains unclear how the vaccine impacts pregnant women and children, and individuals in those demographic groups may have to wait longer to receive the vaccine.

Pfizer’s CEO, Albert Bourla, said of yesterday’s meeting: “If the FDA issues an authorization, stand at the ready to bring this vaccine to people in the U.S. in an effort to help combat this devastating pandemic.”

So what’s next, and how soon could this vaccine be distributed?

Market Movers & Predictions

Thanks for reading once again! And don’t worry, I didn’t forget:

Here’s where you can go to check your answer!

Know someone who should be getting these Bullet Briefs? Make sure to send them over to to subscribe.

Your biggest fan,


Fredrick Frost

P.S.  How useful did you find today’s Morning Bullets? 

Not useful

It was ok

It was good 

Very Useful

Author: Fredrick Frost

Fedrick Frost is the Editor-in-Chief of Morning Bullets. He mainly writes about Politics, The Economy and breaking news. With over 35 years in jounralism he has been influential in helping the morning bullets newsletter readers be informed every morning.